NASDAQ:OPHT IVERIC bio (OPHT) Stock Price, News & Analysis → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free OPHT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.13▼$1.3952-Week Range N/AVolumeN/AAverage Volume159,109 shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get IVERIC bio alerts: Email Address Ad The Tomorrow InvestorThe Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest About IVERIC bio Stock (NASDAQ:OPHT)IVERIC bio, Inc. is a biopharmaceutical company which engages in discovering, developing, and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in New York, NY.Read More Ad The Tomorrow InvestorThe Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest OPHT Stock News HeadlinesNovember 5, 2023 | morningstar.comGossamer Bio Inc GOSSJune 30, 2023 | msn.comIveric Bio ticks higher as it sees sale to Astellas closing July 11May 8, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. June 29, 2023 | msn.comIveric Bio falls amid concern about Astellas dealMay 6, 2023 | msn.comBaird Downgrades IVERIC bio (ISEE)May 6, 2023 | msn.comApellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric BioMay 2, 2023 | msn.comIveric Bio (NASDAQ:ISEE) Sold for $5.9BMay 1, 2023 | msn.comAstellas to Buy Eye-Drug Maker Iveric Bio for $5.9 BillionMay 8, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. May 1, 2023 | reuters.comAstellas Pharma buys Iveric Bio for $5.9 billionApril 30, 2023 | msn.comAstellas Pharma to Buy Iveric Bio for $5.9 BillionApril 30, 2023 | wsj.comAstellas Pharma to Buy Iveric Bio for About $5.9BApril 30, 2023 | msn.comAstellas Pharma agrees to buy Iveric Bio for $5.9 BillionMarch 3, 2023 | markets.businessinsider.comRobert W. Baird Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)March 1, 2023 | marketwatch.comIVERIC Bio Shares Up 14% After Positive Trial Results, 4Q LossesFebruary 17, 2023 | marketwatch.comIveric Bio Shares Rise 16% After FDA Accepts New Drug App for Avacincaptad PegolFebruary 16, 2023 | nasdaq.comDeep Track Capital Now Owns 5.88% of IVERIC bio (ISEE)February 16, 2023 | nasdaq.comRtw Investments Now Owns 0.60% of IVERIC bio (ISEE)September 16, 2022 | seekingalpha.comISEE IVERIC bio, Inc.September 7, 2022 | markets.businessinsider.comWhere IVERIC bio Stands With AnalystsAugust 25, 2022 | markets.businessinsider.comIveric Bio To Announce GATHER2 Trial Data In SeptemberJanuary 18, 2022 | thestreet.comWhy Ophthotech (OPHT) Stock Is Surging TodayAugust 9, 2021 | seekingalpha.comIVERIC bio, Inc. 2021 Q2 - Results - Earnings Call PresentationSee More Headlines Receive OPHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2018Today5/08/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OPHT CUSIPN/A CIK1410939 Webwww.ophthotech.com Phone(212) 845-8200FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$63.09 million Net MarginsN/A Pretax MarginN/A Return on Equity-141.53% Return on Assets-41.88% Debt Debt-to-Equity RatioN/A Current Ratio10.09 Quick Ratio10.09 Sales & Book Value Annual Sales$209.98 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / BookN/AMiscellaneous Outstanding Shares41,420,000Free FloatN/AMarket Cap$1.65 billion OptionableOptionable Beta1.49 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesGlenn P. SblendorioPresident, Chief Executive Officer & DirectorKeith WestbyChief Operating Officer & Senior Vice PresidentDavid F. CarrollChief Financial Officer, Treasurer & SVPKourous A. RezaeiChief Medical Officer & Senior Vice PresidentAbraham ScariaChief Scientific OfficerKey CompetitorsZai LabNASDAQ:ZLABAvadel PharmaceuticalsNASDAQ:AVDLKura OncologyNASDAQ:KURASupernus PharmaceuticalsNASDAQ:SUPNTaro Pharmaceutical IndustriesNYSE:TAROView All Competitors OPHT Stock Analysis - Frequently Asked Questions How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:OPHT) released its quarterly earnings data on Wednesday, October, 31st. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.02. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include iShares Preferred and Income Securities ETF (PFF), Puma Biotechnology (PBYI), Incyte (INCY), Apollo Investment (AINV), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Bausch Health Companies (BHC). This page (NASDAQ:OPHT) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaShocking: One AI startup's revenue could surge 4,735%Manward PressAI “wealth window” is closing June 25thParadigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
